FDA: Drug trials should look into suicidal effects

01/24/2008 | NYTimes.com

The FDA has set new rules requiring drugmakers to pay closer attention to possible suicidal effects of their experimental treatments. Although the change was not announced publicly, the agency has sent letters to drugmakers requiring the new focus, and companies such as Merck & Co., Sanofi-Aventis SA and Eli Lilly and Co. have begun using a detailed suicide assessment in their clinical trials.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC